tomivosertib
Small moleculeexperimental
Clinical trial activity
9 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02605083)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
MKNK2 inhibitor
MKNK1 inhibitor
MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1- Mol. weight
- 340.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4073443 ↗
Also known as
- eft508
- eft508
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05744739 | Phase 1 | Sep 29, 2023 | Effector Therapeutics, National Cancer Institute (NCI), Northwestern University |
| NCT04622007 | Phase 2 | Dec 18, 2020 | Effector Therapeutics, Medpace, Inc. |
| NCT04261218 | Phase 1 | Feb 29, 2020 | Effector Therapeutics, McGill University, Stand Up To Cancer, Translational Research in Oncology |
| NCT03690141 | Phase 2 | Sep 30, 2018 | Effector Therapeutics |
| NCT03616834 | Phase 2 | Jul 25, 2018 | Effector Therapeutics |
| NCT03318562 | Phase 2 | Nov 17, 2017 | Effector Therapeutics, Union Therapeutics |
| NCT03258398 | Phase 2 | Sep 13, 2017 | Effector Therapeutics, Merck KGaA, Pfizer, Union Therapeutics |
| NCT02937675 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Effector Therapeutics |
| NCT02605083 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Effector Therapeutics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Effector Therapeutics | For profit | 9 | 7 | 2 | 2015 |
| Union Therapeutics | For profit | 2 | 0 | 1 | 2017 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2020 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Pfizer | For profit | 1 | 0 | 1 | 2017 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Translational Research in Oncology | Academic/Hospital | 1 | 1 | 1 | 2020 |
10 organizations
Page 1 / 1